Systemic Autoinflammatory Diseases Drug Market by Drug Class, Mechanism of Action, Route of Administration, Distribution Channel, End User

The systemic autoinflammatory disease drug market is experiencing rapid evolution, driven by groundbreaking therapies and intensified focus on personalized patient management. Industry stakeholders face a dynamic environment shaped by shifting regulatory frameworks, economic pressures, and increasing demand for therapies targeting complex inflammatory pathways. Strategic positioning, advanced technology, and supply chain resilience remain central to success.

Market Snapshot: Systemic Autoinflammatory Disease Drug Market

The global systemic autoinflammatory disease drug market is undergoing significant growth, underpinned by strong adoption of targeted biologics and small molecule therapies. The sector benefits from notable advancements in precision medicine, integration of digital health tools, and continual expansion of clinical trial networks. Robust competition among global biopharmaceutical innovators, diverse reimbursement systems, and variable regional disease prevalence further shape market momentum.

Scope & Segmentation of the Autoinflammatory Disease Drug Market

This report delivers a detailed segmentation and regional analysis supported by extensive coverage of drug innovations and care delivery models.

Drug Class: • Interleukin-1 inhibitors (anakinra, canakinumab, rilonacept) • Interleukin-6 receptor blockers (sarilumab, tocilizumab) • Janus kinase inhibitors (baricitinib, tofacitinib, upadacitinib) • Tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab)
Mechanism of Action: • Interleukin-1 blockade • Interleukin-6 receptor blockade • Janus kinase inhibition • Tumor necrosis factor alpha inhibition
Route of Administration: • Intravenous infusion • Oral dosing • Subcutaneous injection
Distribution Channel: • Hospital pharmacies • Online pharmacies • Retail pharmacies
End User: • Clinics • Home care • Hospitals • Specialty centers
Regional Coverage: • Americas: United States (including state-level breakdown), Canada, Mexico, Brazil, Argentina • Europe, Middle East & Africa: United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland • Asia-Pacific: China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan
Leading Companies: • Novartis AG • Swedish Orphan Biovitrum AB • Regeneron Pharmaceuticals, Inc. • Pfizer Inc. • AbbVie Inc. • Roche Holding AG • Amgen Inc. • Bristol-Myers Squibb Company • Novimmune SA • Sanofi S.A.

Key Takeaways for Senior Decision-Makers

Biologics and small molecule innovations are central in redefining the systemic autoinflammatory disease drug landscape, moving strategies toward long-term remission and disease modification.
The market reflects a shift toward biomarker-driven and precision medicine approaches, improving patient stratification and enhancing therapeutic targeting.
Stakeholders must address disparities in access and reimbursement by proactively engaging with payers and aligning portfolio strategies to local regulations and guidelines.
Integration of digital health tools is broadening real-world evidence collection, supporting adaptive clinical trials and streamlining remote patient management.
Strategic partnerships, manufacturing agility, and cross-sector collaborations underpin competitive differentiation while supporting resilience against supply chain risks.

Tariff Impact: Navigating Changing Trade Policies

Upcoming United States trade tariffs will likely influence both active pharmaceutical ingredient sourcing and finished product costs for autoinflammatory therapies. Manufacturers face increased lead times and must reassess supplier diversification, while pricing dynamics are expected to shift as payers respond to evolving cost structures. Adaptive logistics strategies and investments in near-shoring are being explored to maintain supply chain continuity and sustain market access.

Research Methodology & Data Sources

The insights presented are founded on a combination of primary interviews with thought leaders and secondary data from peer-reviewed publications, proprietary drug pipelines, and regulatory filings. Quantitative segment analysis and supply chain modeling further enhance the market picture. Geographic and epidemiological data strengthen the validity of regional insights.

Why This Report Matters

Enables informed investment, portfolio planning, and go-to-market strategy across multiple drug classes and care models.
Equips senior leaders with actionable insights on regulatory, technological, and tariff considerations critical to sustaining market relevance and growth.

Conclusion

Autoinflammatory drug market dynamics are evolving rapidly in response to innovation, regulation, and global supply trends. Senior decision-makers equipped with this report will be positioned to anticipate challenges and capture emerging opportunities in a shifting therapeutic environment.

This product will be delivered within 1-3 business days.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

5.1. Emergence of targeted IL-1 and IL-18 inhibitors in late-stage clinical trials for treating systemic autoinflammatory diseases
5.2. Adoption of precision medicine approaches using genetic profiling to guide therapeutic selection in autoinflammatory conditions
5.3. Expansion of reimbursement frameworks to support high-cost biologics for rare autoinflammatory disease patients
5.4. Increasing strategic partnerships between biotech firms and academic research centers for novel autoinflammatory drug targets
5.5. Advancements in oral small molecule therapies for periodic fever syndromes demonstrating improved patient compliance
5.6. Development of long-acting injectable formulations to reduce dosing frequency and improve adherence in autoinflammatory treatments
5.7. Rising interest in NLRP3 inflammasome inhibitors as a next-generation therapeutic class for systemic autoinflammatory disorders
5.8. Integration of real-world evidence and patient registries to inform health technology assessments for autoinflammatory drug approvals
5.9. Regulatory initiatives accelerating orphan drug designations and fast-track approvals for systemic autoinflammatory disease therapies
5.10. Surge in investment and M&A activity focused on startups developing gene therapies for monogenic autoinflammatory diseases

6. Market Insights

6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Systemic Autoinflammatory Diseases Drug Market, by Drug Class

8.1. Introduction
8.2. Il-1 Inhibitors
8.2.1. Anakinra
8.2.2. Canakinumab
8.2.3. Rilonacept
8.3. Interleukin-6 Receptor Blockade
8.3.1. Sarilumab
8.3.2. Tocilizumab
8.4. Jak Inhibitors
8.4.1. Baricitinib
8.4.2. Tofacitinib
8.4.3. Upadacitinib
8.5. Tnf Inhibitors
8.5.1. Adalimumab
8.5.2. Etanercept
8.5.3. Infliximab

9. Systemic Autoinflammatory Diseases Drug Market, by Mechanism of Action

9.1. Introduction
9.2. Interleukin-1 Blockade
9.3. Interleukin-6 Receptor Blockade
9.4. Janus Kinase Inhibition
9.5. Tumor Necrosis Factor Alpha Inhibition

10. Systemic Autoinflammatory Diseases Drug Market, by Route of Administration

10.1. Introduction
10.2. Intravenous Infusion
10.3. Oral Administration
10.4. Subcutaneous Injection

11. Systemic Autoinflammatory Diseases Drug Market, by Distribution Channel

11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies

12. Systemic Autoinflammatory Diseases Drug Market, by End User

12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
12.5. Specialty Centers

13. Americas Systemic Autoinflammatory Diseases Drug Market

13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina

14. Europe, Middle East & Africa Systemic Autoinflammatory Diseases Drug Market

14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland

15. Asia-Pacific Systemic Autoinflammatory Diseases Drug Market

15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan

16. Competitive Landscape

16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Swedish Orphan Biovitrum AB
16.3.3. Regeneron Pharmaceuticals, Inc.
16.3.4. Pfizer Inc.
16.3.5. AbbVie Inc.
16.3.6. Roche Holding AG
16.3.7. Amgen Inc.
16.3.8. Bristol-Myers Squibb Company
16.3.9. Novimmune SA
16.3.10. Sanofi S.A.

17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix

List of Figures

FIGURE 1. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET: RESEARCHAI
FIGURE 26. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET: RESEARCHSTATISTICS
FIGURE 27. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET: RESEARCHCONTACTS
FIGURE 28. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET: RESEARCHARTICLES

List of Tables

TABLE 1. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 125. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 126. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 127. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 128. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 129. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 130. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 131. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 132. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 133. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 136. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 137. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 144. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 145. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 146. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 147. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 148. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 149. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 154. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 155. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 236. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 237. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 240. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 241. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 246. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 247. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2024 (USD MILLION)
TABLE 258. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2025-2030 (USD MILLION)
TABLE 259. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 264. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 265. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MIL

Samples

LOADING...

Companies Mentioned

The companies profiled in this Systemic Autoinflammatory Diseases Drug market report include:

Novartis AG
Swedish Orphan Biovitrum AB
Regeneron Pharmaceuticals, Inc.
Pfizer Inc.
AbbVie Inc.
Roche Holding AG
Amgen Inc.
Bristol-Myers Squibb Company
Novimmune SA
Sanofi S.A.

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3141EUR$3,545USD£2,717GBP €3490EUR$3,939USD£3,019GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3388EUR$3,824USD£2,931GBP €3764EUR$4,249USD£3,257GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4592EUR$5,183USD£3,973GBP €5102EUR$5,759USD£4,414GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€5557EUR$6,272USD£4,808GBP €6174EUR$6,969USD£5,342GBP

Systemic Autoinflammatory Diseases Drug Market by Drug Class, Mechanism of Action, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030

Market Snapshot: Systemic Autoinflammatory Disease Drug Market

Scope & Segmentation of the Autoinflammatory Disease Drug Market

Key Takeaways for Senior Decision-Makers